Nicox reports financial results for the nine months to September 2012
October 24, 2012
Third quarter operational summary
Following the completion of the worldwide in-licensing agreement in June 2012 with Rapid Pathogen
Screening, Inc (RPS®) for several innovative diagnostic tests, including AdenoPlus™, Nicox has been building up its commercial organization in the United States (US) and in Europe. In August 2012, Nicox
strengthened its US business operations with the appointment of Jason Menzo as Director of Marketing,
Mark Puwal as National Director of Sales and Jason Werner as Director of Commercial Development &
Strategic Alliances for Nicox Inc., its US subsidiary. These followed the appointment of Jerry St. Peter as
Executive Vice President and General Manager of Nicox Inc. in March 2012 and Philippe Masquida as
Executive Vice-President, Managing Director of European Operations in April 2012.
In August 2012, Nicox Pharma, a new subsidiary, was created. Its purpose is to organize the Group’s global
commercial activities outside of North America. In September 2012, certain rights related to the diagnostic
tests in-licensed from RPS® were sub-licensed to Nicox Inc. for the US and Canada and to Nicox Pharma
for the rest of the world.
Read the whole press release on the pdf file: